SGLT-2 Inhibitors
Sodium-glucose cotransporters SGLT1 (also known as SLC5A1) and SGLT2 (also known as SLC5A2) are important mediators of epithelial glucose transport. While SGLT1 accounts for most of the dietary glucose uptake in the intestine, SGLT2 is responsible for the majority of glucose reuptake in the tubular system of the kidney. Mutations in the SLC5A1 gene cause glucose/galactose malabsorption, whereas mutations in SLC5A2 are associated with glucosuria. Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by high blood glucose levels. It is associated with high cardiovascular (CV) risk and renal complications. SGLT2 inhibitors (SGLT2i) are the newest class of oral anti-hyperglycemic agents that have been approved for the treatment of diabetes mellitus. SGLT2i inhibit the absorption of glucose from the proximal tubule of the kidney causing glucosuria. SGLT2i also called as gliflozins, reduce glycated hemoglobin by 0.5%-1.0% and have displayed excellent cardioprotective and renoprotective effects. Four SGLT2i, i.e., Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin, are currently commercially available in many countries for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. BioVision is pleased to offer nine structurally diverse SGLT2 inhibitors as well as one DiscoveryPak™ SGLT2 Inhibitors Set for research.
